Skip to main content

View full-text article in PMC

. 2014 Jun 14;20(22):6912–6917. doi: 10.3748/wjg.v20.i22.6912

Table 2.

Serum adipokine concentrations

	Adiponectin, μg/mL	Leptin, ng/mL	TGF-β1, pg/mL	Chemerin, ng/mL	Resistin, ng/mL	Visfatin, ng/mL
Crohn’s disease
Before treatment (n = 24)	14.7 ± 19.4	8.0 ± 9.1^a	3152 ± 1137	418 ± 193	19.3 ± 12.5^a	23.2 ± 3.2^a
Upon treatment (n = 24)	11.7 ± 6.7	14.9 ± 15.1^c	3261 ± 1327	344 ± 127	17.9 ± 13.2^a	20.4 ± 4.8^a ^c
Ulcerative colitis
Before treatment (n = 16)	9.8 ± 4.1	8.6 ± 6.3^a	4378 ± 361	421 ± 214	23.2 ± 11.0^a	18.8 ± 5.3^a
Upon treatment (n = 16)	13.7 ± 5.3	9.2 ± 7.3	2877 ± 1761	379 ± 208	14.5 ± 4.0^c	21.0 ± 3.5^a
Control group
Healthy subjects (n = 16)	9.3 ± 3.0	16.5 ± 10.1	3027 ± 809	355 ± 69	10.7 ± 1.1	14.1 ± 5.4

^a

P < 0.05 vs control group;

^c

P < 0.05 vs before treatment. TGF: Tumor growth factor.